首页> 外文期刊>European archives of oto-rhino-laryngology: Official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) >Palatal implants in the treatment of obstructive sleep apnea: A randomised, placebo-controlled single-centre trial
【24h】

Palatal implants in the treatment of obstructive sleep apnea: A randomised, placebo-controlled single-centre trial

机译:骨植入物治疗阻塞性睡眠呼吸暂停:一项随机,安慰剂对照的单中心试验

获取原文
获取原文并翻译 | 示例
           

摘要

Palatal implants have been used to treat snoring and mild to moderate obstructive sleep apnea (OSA). Two previous controlled trials have published conflicting results regarding the effects of palatal implants on objective outcome measures, although they both could demonstrate superiority over placebo. The aim of the present study was to assess the effects of palatal implants in patients with mild to moderate sleep apnea in a randomised, placebocontrolled trial. Twenty-two patients with mild to moderate OSA (AHI 18 ± 5, BMI 28 ± 3, age 51 ± 13 years) due to palatal obstruction were enrolled in this randomised, double-blind, placebo-controlled trial. Respiratory parameters and sleep efficiency (evaluated by polysomnography), snoring (evaluated by the bed partner), and daytime sleepiness (evaluated by ESS) were assessed before and 90 days after surgery. One patient in each group did not show up for follow-up. The AHI, HI and LSAT showed statistically significant improvement in the treatment group (p<0.05). Snoring as rated by bed partners also showed statistically significant improvement within the treatment group (p = 0.025). There was no statistical difference when comparing the means of the treatment group with the placebo group. There were no peri- or post-operative complications and no extrusions during the follow-up period. The study supports the idea that palatal implants lead to a reduction in respiratory events in patients with mild to moderate OSA, although a statistically significant superiority of palatal implants over placebo could not be demonstrated in this trial.
机译:tal骨植入物已用于治疗打和轻度至中度阻塞性睡眠呼吸暂停(OSA)。先前的两项对照试验已发表了关于of植入物对客观结局指标的影响的相互矛盾的结果,尽管它们均可以证明优于安慰剂。本研究的目的是在一项随机安慰剂对照试验中评估mild植入物对轻度至中度睡眠呼吸暂停患者的作用。这项随机,双盲,安慰剂对照试验纳入了22例因pa骨阻塞导致的轻度至中度OSA(AHI 18±5,BMI 28±3,年龄51±13岁)的患者。在手术前和手术后90天评估呼吸参数和睡眠效率(通过多导睡眠监测仪评估),打nor(由床伴侣评估)和白天嗜睡(由ESS评估)。每组中没有一名患者出现随访。 AHI,HI和LSAT在治疗组中显示出统计学上的显着改善(p <0.05)。卧床伴侣打的结果在治疗组中也显示出统计学上的显着改善(p = 0.025)。比较治疗组和安慰剂组的均值无统计学差异。随访期间无围手术期或术后并发症,无挤压。这项研究支持以下观点:pa骨植入物可导致轻度至中度OSA患者的呼吸事件减少,尽管该试验未能证明not骨植入物在统计学上优于安慰剂。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号